Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03099304 · ClinicalTrials.gov registry record · Phase 2
A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo
A Phase 2 study of Vitiligo, sponsored by Incyte Corporation.
- Completed
- Registry status
- Phase 2
- Development phase
- 157
- Enrollment target
- 20
- Study locations
NCT03099304 is a Phase 2 study of Vitiligo that has completed, run by Incyte Corporation. The registered enrollment target is 157 participants, below the 1,114-participant average among 15 other Vitiligo trials with a reported enrollment target (86% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT03099304, a Phase 2 study of Vitiligo, has completed, sponsored by Incyte Corporation.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 157 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
Conditions Studied
Interventions
- DRUG Vehicle cream
- DRUG Ruxolitinib cream
Study Locations (20)
California
- THE VITILIGO & PIGMENTATION INSTITUE OF SOUTHERN CALIFORNIA, 5670 Wilshire Boulevard - Los Angeles
- DERMATOLOGY RESEARCH ASSOCIATES- LOS ANGELES, 8930 S Sepulveda Blvd - Los Angeles
- DERMATOLOGY SPECIALISTS, 3629 Vista Way - Oceanside
Arkansas
- BURKE PHARMACEUTICAL RESEARCH LLC, 3633 Central Ave - Hot Springs
- NORTHWEST AR CLINICAL TRIALS CENTER, PLLC/HULL DERMATOLOGY, PA, 500 S 52nd Street - Rogers
Indiana
- DAWES FRETZIN CLINICAL RESEARCH GROUP, 8103 Clearvista Parkway - Indianapolis
- DS RESEARCH, 2241 Green Valley Road - New Albany
Massachusetts
- Tufts Medical Center, 260 Tremont Street - Boston
- UNIVERSITY OF MASSACHUESETTS, 364 Plantation Street - Worcester
Alabama
- UNIVERSITY OF ALABAMA AT BIRMINGHAM (UAB), 1802 6th Ave S - Birmingham
Connecticut
- CLINICAL RESEARCH CENTER OF CT, 27 Hospital Avenue - Danbury
Florida
- LEAVITT MEDICAL ASSOCIATES OF FLORIDA INC/ AMERIDERM RESEARCH, 725 W Granada Blvd - Ormond Beach
Georgia
- EMORY UNIVERSITY, 1525 Clifton Road - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2017-06-07 |
| Est. Completion | 2021-09-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03099304
The ClinicalTrials.gov registry entry for NCT03099304 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,114-participant average among 15 other Vitiligo trials with a reported enrollment target (86% lower). The listed sponsor is Incyte Corporation, which has 239 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Vitiligo appearing as the primary indexed condition, and to 2 interventions - of which Vehicle cream is the first listed.
NCT03099304 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Arkansas, Indiana.
Frequently Asked Questions
What is clinical trial NCT03099304 about?
NCT03099304 is a clinical study titled "A Study of INCB018424 Phosphate Cream in Subjects With Vitiligo". The purpose of this study will be to examine the efficacy, safety, and tolerability of ruxolitinib cream in subjects with vitiligo.
What is the current status of trial NCT03099304?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 157 participants. The study started on 2017-06-07. Estimated completion is 2021-09-08.
What conditions does trial NCT03099304 study?
This clinical trial studies the following conditions: Vitiligo.
What interventions are being tested in trial NCT03099304?
The interventions under investigation include: Vehicle cream (DRUG), Ruxolitinib cream (DRUG).
Who is sponsoring clinical trial NCT03099304?
This trial is sponsored by Incyte Corporation, which has 239 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03099304 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Vitiligo
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Daily Topical Rapamycin for Vitiligo
ACTIVE NOT RECRUITING · Phase 2
-
Combined Therapy With Narrow-Band Ultraviolet B Phototherapy and Apremilast for the Treatment of Vitiligo
COMPLETED · Phase 2
-
Evaluation of AMG 714 for Vitiligo
COMPLETED · Phase 2
-
A Study of ATI-50002 Topical Solution for the Treatment of Vitiligo
COMPLETED · Phase 2
-
A Study of DR-01 in Subjects With Alopecia Areata and Vitiligo
RECRUITING · Phase 1
-
A 52-Week Study to Learn About the Safety and Effects of Ritlecitinib in Participants With Nonsegmental Vitiligo
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.